Autres langues Celyad Oncology SA

Actions

CYAD

BE0974260896

Marché Fermé - Euronext Bruxelles Autres places de cotation 17:35:16 26/04/2024			Varia. 5j.	Varia. 1 janv.
0,335 ^EUR	+6,35%		-1,33%	-14,10%

04/04	Celyad Oncology: 7 millions d'euros de trésorerie, visibilité jusqu'au 2e trimestre 2025	AO
04/04	GENFIT : Accor, Kering, Sanofi... les valeurs à suivre aujourd'hui à Paris -	AO

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Celyad Oncology reports full year 2023 financial results and recent business highlights	05/04
Celyad Oncology : Report of the Statutory Auditor on the Consolidated Annual Account 2023 ENG	05/04
Verlies Celyad Oncology flink gedaald	04/04
Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023	04/04
Celyad Oncology Seeks Termination of Reporting Obligations to US SEC	09/02
Celyad heeft voldoende middelen voor minimaal 12 maanden	17/01
Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook	16/01
Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)	20/12
Celyad Oncology CEO Resigns	05/12
Celyad Oncology CEO Steps Down for Personal Reasons	04/12
Celyad announces management change	04/12
Celyad Oncology SA Announces Executive Change	04/12
Celyad Oncology Sa Announces Executive Change	04/12
Celyad Oncology : announces management change	01/12
Celyad Oncology : reports third quarter 2023 financial results and recent business highlights - Form 6-K	24/11
Celyad Oncology SA - Publication of a transparency notification received from Fortress Investment Group LLC	22/11
Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)	21/11
Celyad Oncology : CONVENING LETTER TO THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF 22 DECEMBER 2023 - Form 6-K	21/11
Celyad Oncology SA announced that it has received ?9.794 million in funding from CFIP CLYD (UK) Limited, Fortress Investment Group LLC, Tolefi S.A.	14/11
Celyad heeft voldoende geld tot tweede kwartaal van 2025	09/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Celyad Oncology SA

Actions

CYAD

BE0974260896

Autres langues

Filtres